Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury

Summary

CD39 (ecto-nucleoside triphosphate diphosphohydrolase-1; E-NTPDase-1), is highly expressed on quiescent vascular endothelial cells and efficiently hydrolyzes extracellular ATP and ADP to AMP and ultimately adenosine. This action blocks extracellular nucleotide-dependent platelet aggregation and abrogates endothelial cell activation. However, CD39 enzymatic activity is rapidly lost following exposure to oxidant stress. Modulation of extracellular nucleotide levels may therefore play an important role in the pathogenesis of vascular injury. Acute ischemic injury of the bowel is a serious medical condition characterized by high mortality rates with limited therapeutic options. Here we evaluate the effects of cd39-deletion in mutant mice and the use of supplemental NTPDase or adenosine in influencing the outcomes of intestinal ischemia-reperfusion. Wild-type, cd39null, or hemizygous cd39-deficient mice were subjected to intestinal ischemia. In selected animals, 0.2 U/g apyrase (soluble NTPDase) was administered prior to re-establishment of blood-flow. In parallel experiments adenosine/amrinone was infused over 60 min during reperfusion periods. Survival rates were determined, serum and tissue samples were taken. Intravital videomicroscopy and studies of vascular permeability were used to study platelet-endothelial cell interactions and determine capillary leakage. In wild-type animals, ischemia reperfusion injury resulted in 60% mortality within 48 hours. In mutant mice null or deficient for cd39, ischemia reperfusionrelated death occurred in 80% of animals. Apyrase supplementation protected all wild-type animals from death due to intestinal ischemia but did not fully protect cd39-null and cd39-hemizygote mice. Adenosine/amrinone treatment failed to improve survival figures. In wild type mice, platelet adherence to postcapillary venules was significantly decreased and vascular integrity was well preserved following apyrase administration. In cd39- null mice, ischemia-reperfusion induced marked albumin leakage indicative of heightened vascular permaeability when compared to wild-type animals (p=0.04). Treatment with NTPDase or adenosine supplementation abrogated the increased vascular permeability in ischemic jejunal specimens of both wild-type mice and cd39-null. CD39 activity modulates platelet activation and vascular leak during intestinal ischemia reperfusion injury in vivo. The potential of NTPDases to maintain vascular integrity suggests potential pharmacological benefit of these agents in mesenteric ischemic injury.

Keywords

Ischemia reperfusion injury - small intestine - platelet activation - endothelial cell activation - videomicroscopy

• References

• 1 Thiagarajan RR, Winn RK, Harlan JM. The role of leukocyte and endothelial adhesion molecules in ischemia-reperfusion injury. Thromb Haemost 1997; 78: 310-4.
• 2 Milazzo VJ, Ferrante RJ, Sabido F. et al. Time course of leukocyte adhesion to endothelium in ischemia-reperfusion. J Surg Res 1996; 61: 139-42.
• 3 Squadrito F, Altavilla D, Squadrito G. et al. The involvement of tumor necrosis factoralpha in the protective effects of 17 beta oestradiol in splanchnic ischaemia-reperfusion injury. Br J Pharmacol 1997; 121: 1782-8.
• 4 Deshmukh DR, Mirochnitchenko O, Ghole VS. et al. Intestinal ischemia and reperfusion injury in transgenic mice overexpressing copper-zinc superoxide dismutase. Am J Physiol 1997; 273: C1130-5.
• 5 Rose S, Floyd RA, Eneff K. et al. Intestinal ischemia: reperfusion mediated increase in hydroxyl free radical fromation as reported by salicylate hydroxylation. Shock 1994; 01: 452-6.
• 6 Frenette PS, Moyna C, Hartwell DW. et al. Platelet-endothelial interactions in inflamed mesenteric venules. Blood 1998; 91: 1318-24.
• 7 Massberg S, Enders G, Leiderer R. et al. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood 1998; 92: 507-15.
• 8 Cywes R, Packham MA, Tietze L. et al. The role of platelets in hepatic allograft preservation injury in the rat. Hepatology 1993; 18: 635-47.
• 9 Lefer AM, Lefer DJ. Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol 1993; 33: 71-90.
• 10 Marcus AJ, Broekman MJ, Drosopoulos JHF. et al. Thromboregulation by endothelial cells Significance for occlusive vascular diseases. Arterioscler Thromb Vasc Biol 2001; 21: 178-82.
• 11 Robson SC, Kaczmarek E, Siegel JB. et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 1997; 185: 153-63.
• 12 Dubiak GR, El-Moatassim C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol 1993; 265: C577.
• 13 Seligmann C, Kupatt C, Becker BF. et al. Adenosine endogenously released during early reperfusion mitigates postischemic myocardial dysfunction by inhibiting platelet adhesion. J Cardiovasc Pharmacol 1998; 32: 156-63.
• 14 Burnstock G. Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 2002; 22: 364-73.
• 15 Body SC. Platelet activation and interactions with the microvasculature. J Cardiovasc Pharmacol 1996; 27 Suppl (01) S13-25.
• 16 Goepfert C, Imai M, Brouard S. et al. CD39 modulates endothelial cell activation and apoptosis. Mol Med 2000; 06: 591-603.
• 17 Candinas D, Koyamada N, Miyatake T. et al. Loss of rat glomerular ATP diphosphohydrolase activity during reperfusion injury is associated with oxidative stress reactions. Thromb Haemost 1996; 76: 807-12.
• 18 Imai M, Takigami K, Guckelberger O. et al. Modulation of nucleotide triphosphate diphosphohydrolase-1 (NTPDase-1) cd39 in xenograft rejection. Mol Med 1999; 05: 743-52.
• 19 Koyamada N, Miyatake T, Candinas D. et al. Apyrase administration prolongs discordant xenograft survival. Transplantation 1996; 62: 1739-43.
• 20 Enjyoji K, Sevigny J, Lin Y. et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999; 05: 1010-7.
• 21 Kauffman RF, Schenck KW, Utterback BG. et al. In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides. J Pharmacol Exp Ther 1987; 242: 864-72.
• 22 Fry DL, Mahley RW, Weisgraber KH. et al. Simultaneous accumulation of Evans blue dye and albumin in the canine aortic wall. Am J Physiol 1977; 233: H66-79.
• 23 Barone GW, Farley PC, Conerly JM. et al. Morphological and functional techniques for assessing endothelial integrity: the use of Evans blue dye, silver stains, endothelial derived relaxing factor. J Card Surg 1989; 04: 140-8.
• 24 Mullane KM, Kraemer R, Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J Pharmacol Methods 1985; 14: 157-67.
• 25 Sévigny J, Levesque FP, Grondin G. et al. Purification of the blood vessel ATP diphosphohydrolase, identification and localization by immunological techniques. Biochim Biophys Acta 1997; 1334: 73-88.
• 26 Baykov AA, Evtushenko OA, Avaeva SM. A malachite green procedure for orthophosphate determination and its use in alkaline phosphatase-based enzyme immunoassay. Analyt Biochem 1988; 171: 266-70.
• 27 Bradford MM. A rapid and sensitive method for quantification of microgram quantities of protein utilizing the principle of proteindye binding. Analyt Biochem 1976; 72: 248-54.
• 28 Gayle III RB, Maliszewski CR, Gimpel SD. et al. Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39. J Clin Invest 1998; 101: 1851-9.
• 29 Unal S, Demirkan F, Arslan E. et al. Comparison of ischemic and chemical preconditioning in jejunal flaps in the rat. Plast Reconstr Surg 2003; 112: 1024-31.
• 30 Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001; 41: 775-87.
• 31 Robson SC, Sevigny J, Imai M. et al. Thromboregulatory potential of endothelial CD39/nucleoside triphosphate diphosphohydrolase: modulation of purinergic signalling in platelets. Emerging Therapeutic Targets 2000; 04: 155-71.
• 32 Imai M, Goepfert C, Kaczmarek E. et al. CD39 modulates IL-1 release from activated endothelial cells. Biochem Biophys Res Commun 2000; 270: 272-8.
• 33 Josko J, Gwozdz B, Jedrzejowska-Szypulka H. et al. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Med Sci Monit 2000; 06: 1047-52.
• 34 Xu F, Severinghaus JW. Rat brain VEGF expression in alveolar hypoxia: possible role in high-altitude cerebral edema. J Appl Physiol 1998; 85: 53-7.
• 35 Nilsson B, Friman S, Wallin M. et al. The liver protective effect of ischemic preconditioning may be mediated by adenosine. Transpl Int 2000; 13 Suppl: (01) S558-561.
• 36 de Jonge R, de Jong JW, Giacometti D. et al. Role of adenosine and glycogen in ischemic preconditioning of rat hearts. Eur J Pharmacol 2001; 414: 55-62.
• 37 Lee HT, Emala CW. Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors. Am J Physiol Renal Physiol 2000; 278: F380-F387.
• 38 Sakata C, Tanaka H, Takemura S. et al. Postischemic intraportal adenosine administration protects against reperfusion injury of canine liver. J Hepatobiliary Pancreat Surg 2000; 07: 78-85.
• 39 Sakaguchi T, Sawa Y, Kitakaze M. et al. Ecto-5’-nucleotidase plays a role in the cardioprotective effects of heat shock protein 72 in ischemia-reperfusion injury in rat hearts. Cardiovasc Res 2000; 47: 74-80.
• 40 Frassetto SS, Schetinger MR, Schierholt R. et al. Brain ischemia alters platelet ATP diphosphohydrolase and 5’-nucleotidase activities in naïve and preconditioned rats. Braz J Med Biol Res 2000; 33: 1369-77.